Miromatrix Medical Stock Soars 236% After It Agrees to Be Bought By United Therapeutics

Dow Jones2023-10-30

Miromatrix Medical Inc.’s stock jumped 235.6% in premarket trades on Monday after the company agreed to be acquired by United Therapeutics Corp. for $3.25 per share in cash, or about $91 million.

The deal also includes a milestone payment of $1.75 per share in cash upon the achievement of clinical development of Miromatrix’s development-stage, fully-implantable manufactured kidney product, Mirokidney by Dec. 31, 2025.

The price of $3.25 a share amounts to a premium of approximately 170% to the 30-day volume-weighted average trading price of Miromatrix’s common stock as of Friday.

Miromatrix’s board has recommended that Miromatrix’s stockholders agree to the offer. The deal is expected to close in the fourth quarter.

United Therapeutics’s stock is down 21% so far in 2023, compared to a 20.8% rise by the Nasdaq.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment